Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
IN RE: Bayer Corp. Combination Aspirin Products Marketing and Sales Practices Litigation
Case Number:
1:09-md-02023
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
- Bartlit Beck
- Coughlin Midlige
- DLA Piper
- Douglas & London
- FeganScott
- Ford Law Firm LLP
- Fox Smith
- Hagens Berman
- Heidell Pittoni
- Heninger Garrison
- Kelley Drye
- Kolman Law
- Nealon Scialabba
- Niemeyer Grebel
- O'Leary Shelton
- Reed Smith
- Shindler Anderson
- Shook Hardy
Companies
Sectors & Industries:
-
May 17, 2012
Bayer Pays $15M To Soothe Consumers In Aspirin MDL
Bayer Corp. has agreed to pay $15 million to resolve class action claims that it misled consumers into believing its combination aspirin drugs had received regulatory approval, according to a settlement motion filed in New York federal court Wednesday.
-
September 16, 2009
Bayer Asks Court To Scrap MDL On Aspirin Marketing
Bayer Healthcare LLC has asked a federal judge in New York to scrap a multidistrict litigation case that accuses the pharmaceutical giant of illegally marketing its combination aspirins as a way to fend off heart and bone disease.
-
July 13, 2009
Aspirin Marketing MDL Bears Down on Bayer
Consumers accusing Bayer Healthcare LLC of promoting its aspirin products without regulatory approval have banded together in multidistrict litigation, filing a master complaint alleging the pharmaceutical giant illegally marketed its combination aspirins as a way to fend off heart and bone disease.